• +1-646-491-9876
    • +91-20-67278686

    Search

    Amyloidosis Pipeline Review H2 2017

    Amyloidosis Pipeline Review H2 2017

    • Report Code ID: RW0001884153
    • Category Pharmaceuticals
    • No. of Pages 157
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Amyloidosis - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H2 2017, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape.

    Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Amyloidosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Amyloidosis (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Amyloidosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 7, 7, 6 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.

    Amyloidosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    Amyloidosis - Overview 6
    Amyloidosis - Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Pipeline by Universities/Institutes 11
    Products under Development by Companies 12
    Products under Development by Universities/Institutes 14
    Amyloidosis - Therapeutics Assessment 15
    Assessment by Target 15
    Assessment by Mechanism of Action 17
    Assessment by Route of Administration 19
    Assessment by Molecule Type 21
    Amyloidosis - Companies Involved in Therapeutics Development 23
    Alnylam Pharmaceuticals Inc 23
    Amgen Inc 23
    Arcturus Therapeutics Inc 24
    Bsim2 24
    Celgene Corp 25
    GlaxoSmithKline Plc 25
    Ionis Pharmaceuticals Inc 26
    Johnson & Johnson 26
    Millennium Pharmaceuticals Inc 27
    Neurimmune Holding AG 27
    Novartis AG 28
    Oncopeptides AB 28
    Pfizer Inc 29
    Prothena Corp Plc 29
    R Pharm 30
    Regeneron Pharmaceuticals Inc 30
    SOM Biotech SL 31
    Spectrum Pharmaceuticals Inc 31
    Amyloidosis - Drug Profiles 32
    AG-10 - Drug Profile 32
    ALN-ANG - Drug Profile 33
    ALN-TTRsc02 - Drug Profile 34
    CAEL-101 - Drug Profile 35
    canakinumab - Drug Profile 37
    carfilzomib - Drug Profile 43
    CLR-01 - Drug Profile 55
    daratumumab - Drug Profile 57
    dezamizumab - Drug Profile 73
    dezamizumab + GSK-2315698 - Drug Profile 74
    doxycycline hyclate - Drug Profile 75
    EDE-1307 - Drug Profile 76
    GSK-2315698 - Drug Profile 77
    GSK-3039294 - Drug Profile 78
    inotersen sodium - Drug Profile 79
    ixazomib citrate - Drug Profile 83
    LUNAR-TTR - Drug Profile 93
    melphalan - Drug Profile 94
    melphalan flufenamide - Drug Profile 98
    Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile 100
    Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders - Drug Profile 101
    NEOD-001 - Drug Profile 102
    NI-301 - Drug Profile 107
    NPT-289 - Drug Profile 108
    Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile 109
    patisiran - Drug Profile 110
    pomalidomide - Drug Profile 118
    PRX-004 - Drug Profile 125
    RPH-104 - Drug Profile 126
    Small Molecule to Inhibit Amyloid Beta Peptide for Alzheimer's Disease and Amyloidosis - Drug Profile 127
    Small Molecules to Activate ATF6 for Amyloidosis - Drug Profile 128
    Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile 129
    Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Drug Profile 130
    Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile 131
    tafamidis meglumine - Drug Profile 132
    tolcapone - Drug Profile 135
    Amyloidosis - Dormant Projects 137
    Amyloidosis - Discontinued Products 138
    Amyloidosis - Product Development Milestones 139
    Featured News & Press Releases 139
    Appendix 153
    Methodology 153
    Coverage 153
    Secondary Research 153
    Primary Research 153
    Expert Panel Validation 153
    Contact Us 153
    Disclaimer 154

    List of Tables

    Number of Products under Development for Amyloidosis, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Amyloidosis - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
    Amyloidosis - Pipeline by Amgen Inc, H2 2017
    Amyloidosis - Pipeline by Arcturus Therapeutics Inc, H2 2017
    Amyloidosis - Pipeline by Bsim2, H2 2017
    Amyloidosis - Pipeline by Celgene Corp, H2 2017
    Amyloidosis - Pipeline by GlaxoSmithKline Plc, H2 2017
    Amyloidosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
    Amyloidosis - Pipeline by Johnson & Johnson, H2 2017
    Amyloidosis - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
    Amyloidosis - Pipeline by Neurimmune Holding AG, H2 2017
    Amyloidosis - Pipeline by Novartis AG, H2 2017
    Amyloidosis - Pipeline by Oncopeptides AB, H2 2017
    Amyloidosis - Pipeline by Pfizer Inc, H2 2017
    Amyloidosis - Pipeline by Prothena Corp Plc, H2 2017
    Amyloidosis - Pipeline by R Pharm, H2 2017
    Amyloidosis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
    Amyloidosis - Pipeline by SOM Biotech SL, H2 2017
    Amyloidosis - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
    Amyloidosis - Dormant Projects, H2 2017
    Amyloidosis - Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development for Amyloidosis, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Alnylam Pharmaceuticals Inc
    Amgen Inc
    Arcturus Therapeutics Inc
    Bsim2
    Celgene Corp
    GlaxoSmithKline Plc
    Ionis Pharmaceuticals Inc
    Johnson & Johnson
    Millennium Pharmaceuticals Inc
    Neurimmune Holding AG
    Novartis AG
    Oncopeptides AB
    Pfizer Inc
    Prothena Corp Plc
    R Pharm
    Regeneron Pharmaceuticals Inc
    SOM Biotech SL
    Spectrum Pharmaceuticals Inc

    Request for Sample

    Report Url https://www.reportsweb.com//amyloidosis-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//amyloidosis-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//amyloidosis-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments